Advertisement

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Opportunities to Optimize Cancer Policies Panel Discussion

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Advertisement

Advertisement




Mar
25
Today In Oncology
FDA Approves Relacorilant With Nab-Paclitaxel for Several Platinum-Resistant Gynecologic Cancers
Awareness of Alcohol-Cancer Link Holds Steady Despite Omission in New US Dietary Guidelines
Myelofibrosis Treatment Landscape Is Poised for Change
AI Model Classifies Challenging Thymic Epithelial Tumors
Study Finds Inferior Survival Among Black Patients With AML, Independent of Cytogenetic Risk
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo